A local lymph node assay to analyse immunosuppressive effects of topically applied drugs.
Topical glucocorticosteroids represent the mainstay of antiinflammatory therapy in the treatment of inflammatory skin diseases. Their clinical use, however, is limited by local and systemic side-effects. Thus, in dermatopharmacology there is a large demand for alternative non-steroidal antiinflammatories. Other than transplantation models, most of the frequently used in vivo test systems for assessment of drug-induced immunosuppression measure changes in inflammatory skin responses by means of skin erythema and edema after challenge of sensitized animals. The aim of this study was to develop an alternative mouse model to detect and analyse immunosuppressive effects of topically applied drugs. On the basis of a modified local lymph node assay, we analysed effects of topical hydrocortisone, dexamethasone, mometasone furoate and FK506 (tacrolimus) during the induction phase of contact hypersensitivity. On 4 consecutive days, NMRI mice were treated on the dorsal surfaces of both ears with increasing concentrations of test compound. During the last 3 days, the mice received in addition the contact sensitizer, oxazolone (1%). On day 5, draining auricular lymph nodes were removed in order to assess lymph node cell counts and perform flow cytometric analysis of lymph node cell subpopulations (CD4+/CD25+, Ia+/CD69+, Ia+/B220+). All test compounds proved to exert significant immunosuppressive effects after topical application, but showed differences in their immunomodulatory potential. In conclusion, the local lymph node assay serves as an appropriate model to characterize immunosuppressive effects of topically applied drugs by measuring immunologically relevant end-points.
Homey
B
B
Department of Dermatology, Heinrich Heine University, Düsseldorf, Germany.
Schuppe
H C
HC
Assmann
T
T
Vohr
H W
HW
Lauerma
A I
AI
Ruzicka
T
T
Lehmann
P
P
D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D003877:Dermatitis, Contact / Q000188:drug therapy; D003907:Dexamethasone / Q000008:administration & dosage; D004353:Drug Evaluation, Preclinical / Q000379:methods; D005260:Female; D006854:Hydrocortisone / Q000008:administration & dosage; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008198:Lymph Nodes / Q000187:drug effects* / Q000276:immunology*; D051379:Mice; D000068656:Mometasone Furoate; D010081:Oxazolone / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity; D011244:Pregnadienediols / Q000008:administration & dosage; D016559:Tacrolimus / Q000008:administration & dosage
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate; D010081:Oxazolone; D003907:Dexamethasone; D006854:Hydrocortisone; D016559:Tacrolimus